Article: How GLP-1 Medications Impact hs-CRP Levels: A Comprehensive Look at Inflammation and Weight Loss
GLP-1 (glucagon-like peptide-1) medications have been gaining attention not only for their role in weight loss but also for their potential benefits in reducing inflammation, as measured by high-sensitivity C-reactive protein (hs-CRP) levels. Inflammation is a key factor in many chronic conditions, including heart disease, type 2 diabetes, and metabolic syndrome. Understanding how GLP-1 medications influence hs-CRP levels can shed light on their broader health benefits beyond weight loss.
What is hs-CRP?
hs-CRP is a biomarker for systemic inflammation, produced by the liver in response to inflammation in the body. Elevated hs-CRP levels have been associated with an increased risk of cardiovascular disease, insulin resistance, and even cancer. Reducing hs-CRP through lifestyle changes, weight loss, or medication can significantly improve overall health and reduce the risk of developing these chronic conditions.
How GLP-1 Medications Work
GLP-1 is a hormone that stimulates insulin release in response to food intake, reduces appetite, slows gastric emptying, and promotes a feeling of fullness. Medications that mimic the action of GLP-1, such as semaglutide (Wegovy and Ozempic) and liraglutide (Saxenda and Victoza), have been used to manage blood sugar levels in type 2 diabetes and are increasingly prescribed for weight loss in non-diabetic individuals.
GLP-1 and Weight Loss
One of the primary benefits of GLP-1 medications is weight loss. Studies have shown that losing weight can reduce inflammation in the body, including lowering hs-CRP levels. Even a modest weight loss of 5-10% has been shown to have a significant impact on reducing systemic inflammation, making GLP-1 medications a powerful tool for not only achieving weight loss but also improving inflammatory markers.
GLP-1 Medications and Inflammation
Several studies have explored the relationship between GLP-1 medications and inflammatory markers like hs-CRP. The research indicates that GLP-1 agonists may reduce systemic inflammation, even independently of weight loss, suggesting anti-inflammatory properties inherent to the drug.
A 2024 study published in Pharma Nutrition found that liraglutide significantly lowered hs-CRP levels in people with obesity, independent of glucose control. The study concluded that GLP-1 receptor agonists could play a role in reducing inflammation-related cardiovascular risk in people living with obesity (1).
A 2018 study in The Lancet Diabetes & Endocrinology examined the effects of semaglutide on inflammatory markers and cardiovascular risk. The results showed that participants taking semaglutide experienced a significant reduction in hs-CRP levels, supporting the idea that these medications can reduce cardiovascular risk by modulating inflammation (2).
A 2021 meta-analysis in The Journal of Diabetes, Obesity & Metabolism also found that GLP-1 receptor agonists,had a significant impact on reducing hs-CRP levels, especially in people who experienced substantial weight loss during treatment. This suggests a dual benefit: lowering body weight and reducing inflammation simultaneously (3).
Mechanisms Behind GLP-1’s Impact on Inflammation
The exact mechanisms by which GLP-1 medications reduce inflammation are still being studied. However, several possible pathways have been proposed:
Reduction in visceral fat: Visceral fat, the fat stored around internal organs, is particularly inflammatory. GLP-1 medications help target visceral fat (through weight loss), which may lead to a decrease in inflammatory markers like hs-CRP.
Improved insulin sensitivity: GLP-1 medications improve insulin sensitivity, which in turn can reduce chronic inflammation associated with insulin resistance and metabolic syndrome.
Direct anti-inflammatory effects: Some research suggests that GLP-1 may have direct anti-inflammatory effects on the immune system, though more studies are needed to confirm this.
Lifestyle Interventions to Further Reduce hs-CRP
While GLP-1 medications can significantly reduce hs-CRP levels, combining them with lifestyle interventions like a whole foods plant-based diet can further enhance these effects. Whole, plant-based foods are naturally anti-inflammatory and can help reduce both visceral fat and systemic inflammation. For example, a diet rich in vegetables, fruits, whole grains, and legumes has been shown to reduce hs-CRP levels, making it a complementary strategy to GLP-1 medications.
What Do I think?
GLP-1 medications offer more than just weight loss—they may also reduce systemic inflammation as measured by hs-CRP levels, contributing to a decreased risk of cardiovascular disease and other inflammation-related conditions. When combined with lifestyle interventions like a plant-based diet and regular exercise, the anti-inflammatory effects of GLP-1 medications can be even more profound, making them a powerful tool in the fight against chronic disease.
If you're considering GLP-1 medication for weight loss or to improve your overall health, it's essential to work with a healthcare provider who can help you monitor not just weight, but also inflammatory markers like hs-CRP. At Lifestyle Medicine Maine, we offer a comprehensive, medically supervised weight loss program that includes lab work to monitor biomarkers like hs-CRP.
Contact us to learn more about how we can help you achieve sustainable weight loss and better health.
References:
Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials. Mozaffari, et al. Pharma Nutrition. (2024) https://www.sciencedirect.com/science/article/abs/pii/S2213434424000355
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. Verma, et al. The Lancet Diabetes and Endocrinology. (2018). https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00466-7/fulltext#:~:text=The%20trials%20took%20place%20from,Novo%20Nordisk.
Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Bray, et al. Diabetes, Obesity and Metabolism. (2021) https://dom-pubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14399
Comments